Bellicum Pharmaceuticals, Inc. (BLCM)

Market Cap	4.56M
Revenue (ttm)	1.51M
Net Income (ttm)	-28.30M
Shares Out	9.50M
EPS (ttm)	-1.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,435
Open	0.321
Previous Close	0.372
Day's Range	0.321 - 0.480
52-Week Range	0.181 - 1.500
Beta	1.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2023

About BLCM

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candida...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 18, 2014
• Employees: 13
• Stock Exchange: OTCMKTS
• Ticker Symbol: BLCM

Financial Performance

In 2022, BLCM's revenue was $1.50 million, a decrease of -75.81% compared to the previous year's $6.20 million. Losses were -$24.97 million, 160.7% more than in 2021.